The developers behind the Sputnik V coronavirus vaccine have claimed that the shot is expected to provide immunity to SARS-CoV-2 infection for at least 2 years, unlike Pfizer, which offers only 3 to 4 months of protection. Alexander Gintsburg, head of the Gamaleya Epidemiology and Microbiology Research Institute, said Pfizer and BioNTech are unlikely to offer protection for more than five months, while Sputnik V, created on the platform also used for the Ebola vaccine, offers greater safety. Gintsburg told the Soloviev Live channel according to TASS. Gintsburg added that Sputnik V had an efficiency of 96%, which exceeded 95% on the 42nd day after the first dose.
Meanwhile, in an official press release, the Gamaleya Center team claimed that the intermediate efficacy based on the results of double-blind, randomized, placebo-controlled phase III clinical trials in 26,000 volunteers was calculated to be over 95%. According to the institute, the Sputnik V vaccine reached an efficacy rate of 91.4 percent among those who received two photos of the vaccine on the 28th day after administration. Sputnik V has currently had approved Phase III clinical trials in progress in Belarus, the United Arab Emirates, Venezuela and other countries, as well as in Phase II-III in India.
Read: OSU health workers are among the first to receive the vaccine
Read: WHO says no indication New COVID variant in UK affects vaccine effectiveness
BREAKDOWN: The second intermediate analysis of clinical trial data showed an efficacy of 91.4% for #SputnikV vaccine on day 28 after the first dose; vaccine efficacy exceeds 95%
42 days after the first dose.
Read more: https://t.co/qfCZ9FG8WH
– Sputnik V (@sputnikvaccine) November 24, 2020
Price somewhere around 10 USD
The National Research Center for Epidemiology and Microbiology, NF Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) said the vaccine is based on a safe and proven platform of immunity to the human adenoviral vector will be priced at around $ 10. “The results that the Sputnik V vaccine demonstrated during phase III clinical trials support our confidence in its high efficacy and complete health safety. This is especially important when it comes to the start of large-scale vaccination of the population, “said Alexander Gintsburg, director of the Gamaleya Center, in a statement. strong long-term immunities to coronavirus infection.
#SputnikV uses 2 different human adenoviral vectors for 2 vaccines to ensure that immunity to the first does not make the second less effective. I offered @AstraZeneca to use one of our vectors so that they can have two vectors in the vaccine. AZ confirmed. https://t.co/ft4ULcD4T5
– Sputnik V (@sputnikvaccine) December 11, 2020
Read: Germany asks EU agency to approve vaccine before Christmas
Read: Pentagon chief Christopher Miller receives COVID-19 vaccine, says “It didn’t hurt”